Department of Etiology, Qidong People's Hospital/Qidong Hospital Affiliated to Nantong University; Qidong Liver Cancer Institute, Qidong, Jiangsu 226200, China
Abstract:Objective To analyze the mortality trend of bladder cancer among residents in Qidong, Jiangsu Province from 1972 to 2016, so as to provide the basis for the prevention and treatment strategy of bladder cancer in Qidong. Methods The data of bladder cancer was collected from Qidong Cancer Registry.The crude mortality rate ( CR ), age-standardized rate by Chinese population in 2000 (CASR) and world population in 1960 ( WASR ), truncated rate (35-64 years) and cumulative rate ( 0-74 years ) were calculated. The annual percent change ( APC ) was used to analyze the trend of mortality in bladder cancer. Results During from 1972 to 2016, There were 1 497 deaths due to bladder cancer in Qidong from 1972 to 2016. The CR, CASR and WASR were 2.96/105, 1.83/105 and 1.80/105, respectively. The APCs in CR, CASR, WASR of bladder cancer were 5.29%, 1.86% and 1.81%, respectively ( P<0.05 ), showing upward trends. The truncated rate, cumulative rate and cumulative risk were 1.47/105, 0.17% and 0.17%, respectively. The CR, CASR and WASR in males were 4.71/105, 2.97/105 and 3.31/105, respectively, which was higher than that of 1.26/105, 0.75/105, and 0.66/105 in females ( P<0.05 ). The APC of CR, CASR and WASR in males were 5.71%, 1.96% and 2.17%, respectively ( P<0.05 ), all showed upward trends. For females, the APC of CR was 4.47% ( P<0.05 ), showing an upward trend, but there was no significant change in CASR and WASR ( P>0.05 ). The CR of bladder cancer was high among people aged more than 55 years. The CR in 55-64-year-old group, 65-74-year-old group and more than 75-year-old group showed upward trends, with APC of 4.50%, 2.22% and 4.51%, respectively ( P<0.05 ). Conclusions From 1972 to 2016, the mortality of bladder cancer in Qidong showed an upward trend, which was relatively high in men and people aged over 55 years.
[1] ANTONI S,FERLAY J,SOERJOMATARAM I,et al.Bladder cancer incidence and mortality:a global overview and recent trends[J].Eur Urol,2017,71(1):96-108. [2] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. [3] 贺宇彤,李道娟,梁迪,等.2014年中国膀胱癌发病和死亡分析[J].中华肿瘤杂志,2018,40(9):647-652. [4] 叶涛,叶章群.膀胱癌研究的新进展[J].现代泌尿生殖肿瘤杂志,2017,9(4):193-197. [5] 陈蓉,许辉,李辉章,等.2010—2014年浙江省肿瘤登记地区膀胱癌发病与死亡分析[J].中国肿瘤,2019,28(2):115-119. [6] 傅忠星,王珏,王烨菁,等.上海市原卢湾区2004—2011年膀胱癌的发病和死亡分析[J].中国肿瘤,2017,26(8):601-606. [7] FANKHAUSER C D,MOSTAFID H.Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle[J].Curr Opin Urol,2018,28(1):88-92. [8] 金佩玉,孙天水,席淑华.影响膀胱癌发生的职业和环境危险因素研究进展[J].环境与职业医学,2017,34(9):840-846. [9] 王顺利,任明华.烟草及职业暴露因素与膀胱癌关系的研究进展[J].医学综述,2017,23(12):2349-2353. [10] JUNG K W,WON Y J,KONG H J,et al.Cancer Statistics in Korea: incidence,mortality,survival,and prevalence in 2016[J].Cancer Res Treat,2019,51(2):417-430. [11] PLOUVIER S D,BONNAL J L,MACHURON F,et al.Impact of age on bladder cancer management practices: a general population study[J].Acta Oncol,2020,59(3):1-5. [12] 黄健,陈旭,林天歆.膀胱癌精准治疗现状与展望[J].中华泌尿外科杂志,2015,36(7):484-486. [13] CHENG L,DAVIDSON D D,WANG M,et al.Telomerase reverse transcriptase(TERT)promoter mutation analysis of benign,malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change[J].Histopathology,2016,69(1):107-113. [14] ANDREW A S,KARAGAS M R,SCHROECK F R,et al.MicroRNA dysregulation and non-muscle-invasive bladder cancer prognosis[J].Cancer Epidemiol Biomarkers Prev,2019,28(4):782-788. [15] LIU S,CHEN Q,WANG Y.MiR-125b-5p suppresses the bladder cancer progression via targeting HK2 and suppressing PI3K/AKT pathway[J].Hum Cell,2020,33(1):185-194. [16] 梁恩利,吴长利,王莹,等.CCNE1、RIP2基因多态性与膀胱癌发病风险的关系[J].天津医药,2015,43(9):1022-1025. [17] JEE Y,JUNG K J,BACK J H,et al.Trajectory of smoking and early bladder cancer risk among Korean young adult men.[J].Cancer Causes Control,2020,31(5):943-949.